Millions of dollars meant to prepare for public health threats went to things like office furniture removal, watchdog says
- HHS misappropriated millions from the Biomedical Advanced Research and Development Authority, a new watchdog report found.
BARDAis responsible for pandemic preparedness.
- The misappropriation of funds spanned ten years.
The Department of Health and Human Services misappropriated millions meant in part for pandemic preparedness, an HHS whistleblower and watchdog report alleged.
HHS's Office of the Assistant Secretary for Preparedness and Response is believed to have misused the Biomedical Advanced Research and Development Authority funds between the fiscal year of 2010 and ending in 2019, according to the investigation conducted by the HHS Inspector General and overseen by the Office of Special Counsel.In a letter, special counsel Henry Kerner told President Joe Biden that he was "deeply concerned about ASPR's apparent misuse of millions of dollars in funding meant for public health emergencies like the one our country is currently facing with the COVID-19 pandemic." (During the 10-year period there have been several people in that role.)
"All expenditures were done in a routine way," Nicole Lurie, who helmed ASPR under the Obama administration told The Washington Post. She also told The Post that she was not interviewed as part of the investigation.Lurie also told The Post: "BARDA was part of ASPR and had a shared mission and used common resources." BARDA was established in December 2006 by Congress. The agency's mission is "to develop and procure needed medical countermeasures, including vaccines, therapeutics, diagnostics, and non-pharmaceutical countermeasures, against a broad array of public health threats, whether natural or intentional in origin," according to HHS.
While this report expands across the tenures of former presidents Barack Obama and Donald Trump, BARDA has been entrapped in several controversies during the COVID-19 pandemic.
Last May, BARDA Director Rick Bright was fired and claimed he was demoted to a job at the National Institutes of Health for pushing back against the use of hydroxychloroquine, an antimalaria drug that Trump embraced as an unproven treatment for COVID-19.Later studies found that the drug was not effective at treating COVID-19, and in June the Food and Drug Administration revoked the emergency use authorization it had in place for the drug.
Bright also filed a federal whistleblower complaint and alleged the HHS gave high-level contracts to companies with political connections.
Bright later told Congress that he was warning about the current COVID-19 pandemic and raised alarms about the US preparedness for an outbreak as early as January but was met with "indifference which then developed into hostility," by HHS."And he said, 'We're in deep s---. The world is. And we need to act,'" Bright recalled. "And I pushed that forward to the highest levels I could in HHS and got no response."
More than 25.5 million Americans have so far been infected with COVID-19 and over 429,000 have died, according to data from Johns Hopkins University.HHS has not replied to a request for comment at the time of publication.
- India's geo imaging satellite launch delayed due to rising COVID-19 cases
- Gartner report reveals global chip shortage may continue till Q2 2022
- COVID-19: Gurugram, Faridabad and Sonipat districts in Haryana worst hit with new infections
- WhatsApp responds to privacy criticism by alleging that other apps and tech companies also show disdain for user privacy
- JK Super Cement's new campaign is an appeal to covid survivors to donate plasma